Overview of Eficur

Quick Facts

Property	Description
Active ingredient	Ceftiofur (as hydrochloride salt)
Form	Suspension for injection
Pharmacological class	Beta-lactam antibiotic, Third-generation cephalosporin
Common use	Treatment of bacterial infections (Broad-spectrum)
Origin	Semisynthetic

Eficur: Identity and Pharmacological Classification

Eficur is a specific veterinary medicinal product that is chemically defined as a semisynthetic beta-lactam antibiotic. The core component, Ceftiofur, is categorized as a third-generation cephalosporin. This advanced classification grants it a broad-spectrum and potent bactericidal effect against susceptible microorganisms. Ceftiofur maintains strong antimicrobial activity due to its ability to resist breakdown by bacterial enzymes, which is essential for managing acute bacterial infections in target patient groups like pigs and cattle.

Composition and Physical Form

The pharmacological substance in this preparation is the active ingredient, ceftiofur hydrochloride, which constitutes a single-ingredient product. Eficur is presented as a sterile, ready-to-use oily suspension for injection, which necessitates administration via a parenteral route. This formulation utilizes an oily suspension base to ensure the stable integration of the active compound. This design is employed to sustain therapeutic levels of the drug in the animal's system over an extended period.

General Purpose and Function

The general purpose of Eficur is to achieve the rapid and decisive elimination of harmful bacteria causing illness. This therapeutic outcome stems from the drug's fundamental bactericidal property—the distinct ability to actively kill bacteria by disrupting their cell wall structure rather than merely suppressing their growth. By causing the irreversible destruction of the bacteria, this third-generation agent supports the host's system in clearing the infection.

Regulatory References

FDA Ceftiofur Technical Section

What side effects are possible with Eficur?

Eficur's official safety profile is based on data categorized by regulatory authorities, outlining both local and systemic adverse reactions. The most consistently documented adverse effects are classified under General Disorders and Administration Site Conditions, which include local inflammatory reactions such as oedema, swelling, or tissue discoloration at the injection site. Regulatory information notes that this discoloration may persist for 28 days or more after administration in cattle.

Systemic and Serious Adverse Reactions

Adverse reactions involving the Immune System Disorders are documented, with systemic allergic reactions (hypersensitivity) noted as occasionally occurring. Anaphylactic reactions are officially documented as occasionally being serious. Other system-organ classes involved include Gastrointestinal Disorders, listing effects such as diarrhea or soft stool, and Nervous System Disorders, with post-approval reports of seizures or collapse linked to related ceftiofur formulations.

Safety Constraints and Special Populations

The product label includes safety restrictions and contraindications based on known risks. It is contraindicated in animals with a documented allergy to ceftiofur or the beta-lactam class of antibiotics. Specific population constraints exist: use is not recommended in pregnant or breeding swine due to unestablished safety, and use in calves intended for veal processing is prohibited. A critical safety note highlights that administering antimicrobials to stressed horses may be associated with a risk of acute and potentially fatal diarrhea. The label also notes that ceftiofur selects for resistant bacterial strains, which is a public health consideration.

Overdose and Emergency Response

The regulatory information concerning overdose for Eficur (Ceftiofur) addresses two distinct risk profiles: low systemic toxicity and accidental human exposure to this cephalosporin antibiotic.

Systemic overdose in the target species is typically associated with a low risk of toxicity and often presents with no clinical signs other than possible transient local reactions at the injection site. No specific antidote for systemic overdose is known or documented in the official labeling.

However, the primary concern is the potential for accidental human exposure. Exposure may initially cause non-severe manifestations such as a skin rash or persistent eye irritation, which warrant seeking medical advice.

More serious outcomes, linked to beta-lactam hypersensitivity, are documented risks requiring immediate intervention. These severe manifestations include swelling of the face, lips or eyes or experiencing difficulty with breathing. When such symptoms occur, the official regulatory guidance mandates that you seek urgent medical attention immediately. Individuals with a known history of hypersensitivity to penicillins or cephalosporins are noted to be at a higher risk of severe allergic reactions upon exposure. In all cases requiring consultation, the package leaflet or label should be presented to the physician.

Therapeutic Uses of Eficur

What Eficur Treats: Main Uses and Benefits

Eficur (Ceftiofur) is commonly used for managing the symptoms of acute bacterial infections across specific therapeutic domains, contributing to improved comfort during symptomatic periods. The therapeutic domains involve conditions where symptoms create noticeable physiological strain.

Core Therapeutic Areas

The medication is used in situations involving certain distressing symptoms related to acute respiratory illness (like Bovine Respiratory Disease and swine pneumonia), severe locomotor impairment due to infection (such as interdigital necrobacillosis/foot rot), and post-partum systemic infection (acute puerperal metritis). These are conditions characterized by periods of heightened symptoms, including high fever, painful lameness, and pronounced lethargy.

“The primary goal of this application is to provide supportive assistance during episodes of sudden symptom escalation, helping to ease the overall symptom burden.”

The core benefit assists with maintaining functional stability and supports general well-being during symptomatic phases.

Quick Fact:
Supports Management of Acute Distress	Helps address symptom clusters that interfere with daily comfort, including fever, difficulty breathing, and severe pain related to inflammation.

Regulatory References

UK Veterinary Medicines Directorate Summary of Product Characteristics

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Eficur?

This medicine, containing ceftiofur, is strictly for use in pigs (swine) and cattle (including lactating dairy cows), as defined by regulatory documents. Its official use profile specifies distinct populations that are either eligible, restricted, or contraindicated.

Classification	Population/Condition
Allowed Species	Pigs and Cattle (including lactating dairy cattle).
Contraindicated	Animals with known hypersensitivity to ceftiofur or other beta-lactam antibiotics (e.g., penicillins, cephalosporins). Poultry and pre-ruminating calves.
Restricted Use	Pregnancy/Lactation (use conditional on veterinary benefit/risk assessment). Use is reserved for cases that have responded poorly to first-line antimicrobials.
Not Recommended	Swine intended for breeding or pregnant swine (safety not evaluated).

The drug is contraindicated if there is known resistance to cephalosporins or beta-lactam antibiotics. Furthermore, official policy prohibits the use of this medication for disease prevention or mass medication, restricting treatment to individual clinical cases.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Eficur (Ceftiofur) based on pharmacodynamic constraints, physical constraints, and known class restrictions.

Interaction Classifications

Classification	Interacting Substance/Class
Pharmacodynamic Antagonism	Bacteriostatic antibiotics (Macrolides, Sulphonamides, Tetracyclines)
Potentiation Risk	Aminoglycosides
Class Restriction	Other beta-lactam antibiotics

Official Interaction Statements

The co-administration of bacteriostatic antibiotics is documented to result in the neutralization of the product's bactericidal properties, confirming a formal pharmacodynamic antagonism. Conversely, Aminoglycosides are noted in regulatory texts as substances that may have a potentiating effect when co-administered. The product is also contraindicated for use in patients with known hypersensitivity to Ceftiofur or to other beta-lactam antibiotics due to the risk of cross-reaction within the same drug class.

It is a mandated procedural constraint that the ready-to-use oily suspension must not be physically mixed with other veterinary medicinal products in the same container. This requirement is based on the absence of formal compatibility studies.

Mechanism of Action

Direct Bactericidal Action via PBP Inhibition

This mechanism covers the drug's core molecular function: the direct, irreversible inactivation of Penicillin-Binding Proteins (PBPs), which are bacterial enzymes essential for cell wall construction. This highly specific interference in the peptidoglycan cross-linkage pathway leads to the structural collapse and subsequent lysis (rupture) of susceptible bacteria, resulting in a bactericidal effect that is the physiological basis for the loss of viability of the pathogen population.

️ Stability Against Bacterial beta-Lactamase Enzymes

The structural classification of Ceftiofur confers inherent stability against many beta-lactamase enzymes, which are bacterial defense mechanisms designed to chemically inactivate beta-lactam antibiotics. By resisting this enzymatic hydrolysis, the active metabolite, Desfuroylceftiofur (DFC), maintains the necessary concentration to effectively bind to the PBP targets. This sustained activity maintains a consistent bactericidal effect against a wide range of susceptible pathogens.

Limitations of the Mechanistic Cascade

The effectiveness of this mechanism is ultimately constrained by the bacteria's ability to resist the active compound. Limitations arise from target site alteration (mutated PBPs with reduced affinity) and the operation of efflux pump systems that rapidly expel the drug from the cell. These mechanisms reduce the effective drug concentration at the site of action, weakening the inhibitory effect and preventing the essential cellular lysis required for the loss of bacterial viability.

Dosage and Administration Information

How to Use Eficur: Administration Guidelines

Eficur (Ceftiofur) is administered strictly as a parenteral suspension for injection, with the route and dosage determined by the target species and condition. The product requires specific preparation and administration protocols to ensure proper use.

Official Administration Scope

Parameter	Detail
Route of Administration	Subcutaneous (SC) injection (primarily for cattle) or Intramuscular (IM) injection (for swine and as an alternate route for cattle).
Dosing Schedule	Swine: 3 mg Ceftiofur per kg of body weight. Cattle: 1 mg Ceftiofur per kg of body weight.
Frequency Pattern	Once daily (q24h) administration for all approved indications.
Course Duration	Swine: 3 consecutive days. Cattle: 3 to 5 consecutive days, depending on the specific condition.

Preparation and Procedural Constraints

Before drawing the dose, the vial of oily suspension must be shaken vigorously until the mixture is homogenous. The correct dosage volume depends on the accurate determination of the animal's body weight to meet the precise mg/kg requirement.

During treatment, subsequent daily injections must be administered at a different site to prevent high volume accumulation. For cattle, the maximum volume administered per single injection site is typically restricted to 10 mL. No specific high-level dosage adjustments for age or organ function are detailed for the target species.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Core Efficacy Studies (Compound X + Compound Y)

Studies evaluated whether the symptoms associated with Condition Z changed following administration of the combination of Compound X and Compound Y. Initial Phase 2 clinical trials examined whether the frequency and severity of episodes changed in a cohort of 150 adult participants over a 12-week period.

Overall, research explores whether there is an effect on quality-of-life scores, specifically related to mobility and pain interference with daily activities. The majority of studies focused on a once-daily dosing regimen.

Dosing and Administration

Studies explored the conditions under which this combination may be associated with differences in measured endpoints, focusing on the timing of administration relative to physical activity.

Studies documented a patient-reported change in symptoms starting around week 4 of treatment, which was maintained throughout the study duration (up to 16 weeks). Different formulations (tablet vs. liquid) were compared to see if absorption rates varied.

This information is for research overview only and does not constitute medical advice or dosage recommendations.

Safety and Tolerability Profile

The primary goal of safety studies was to document the type and frequency of adverse events. The most commonly reported side effects in trials included mild nausea, transient dizziness, and fatigue. These effects were generally reported as mild-to-moderate and was documented to cease within the first two weeks in most cases.

Clinical trials excluded participants with pre-existing liver conditions; therefore, evidence on this population remains limited. Research also looked into potential drug-drug interactions with common over-the-counter pain relievers.

Mechanism of Action (Pre-Clinical)

Early studies investigated whether the compound is associated with a change in anxiety and stress-related symptoms in animal models, specifically by modulating the HPA axis. The biological basis for the combination's activity is under active investigation, though the mechanism of action is still being explored.

Research explored whether the use of a dual-agent therapy resulted in a rapid onset of patient-reported change compared to monotherapy. Pre-clinical research suggests that Compound X may influence the uptake of Compound Y across the blood-brain barrier.

Frequently Asked Questions (FAQ)

Common questions about Eficur (FAQ)

Q: Is it important to take Eficur with food or on an empty stomach?

Official regulatory documents describe Eficur as a liquid suspension that is administered by injection (parenteral route). Because it is not an oral medication (like a pill or capsule), the official instructions regarding administration do not involve taking it with food or on an empty stomach.

Q: What are the most common side effects people report when using Eficur?

According to the official product information for the target animal species, the most consistently documented adverse effect is a local inflammatory reaction at the injection site. This may include symptoms such as temporary swelling, oedema, or discoloration in the tissue where the product was administered. Systemic allergic reactions are officially documented in the product information as occasionally occurring.

Q: Are the side effects of Eficur temporary, or can they last for a long time?

In most cases, any local reactions at the injection site are mild inflammatory reactions that are temporary. However, the official product information documents that slight tissue discoloration at the injection site may remain visible for 28 days or more after administration in cattle.

Q: What should I do if I forget to take a dose of Eficur?

Official documents outline a daily dosing schedule but do not provide explicit instructions for a missed dose. Consulting the prescribing veterinarian is recommended to determine the best approach for the specific situation.

Q: How long do the effects of a single dose of Eficur usually last?

Official pharmacokinetic data describes how the drug moves through the body. The elimination half-life for the active metabolite, desfuroylceftiofur, is reported to be approximately 14.3 hours in swine and over 9 hours in cattle following intramuscular administration.

Q: Can I drink coffee or caffeine while taking Eficur?

Eficur is classified as a veterinary medicine approved strictly for use in pigs and cattle, not for humans. Therefore, the official regulatory documents do not provide any information or warnings concerning interactions with human consumables like coffee or caffeine.

Q: Are there any specific foods or drinks that interact negatively with Eficur?

Since Eficur is a veterinary medicine administered via injection to animals (pigs and cattle), official product documents do not list interactions with human-relevant food or drink products.

Q: What if a woman is planning to become pregnant while using Eficur?

The drug is a veterinary product. Regulatory documents state that its use is not recommended in breeding or pregnant swine because safety has not been fully evaluated in this group. The use of the product in pregnant cattle is subject to a professional benefit/risk assessment performed by the veterinarian.

Q: Is Eficur suitable for children or teenagers?

Eficur is a third-generation cephalosporin and is a veterinary medicine approved strictly for use in pigs and cattle. It is not indicated for use in humans, including children or teenagers.

Q: Are there any restrictions on driving or operating machinery while on Eficur?

This product is a veterinary medicine. Official user safety warnings are directed toward the individual administering the product (e.g., risk of self-injection or allergic reaction) and do not include restrictions on driving or operating machinery.

Q: What kind of studies or research has been done on Eficur?

Official research and regulatory summaries document studies that focus on the drug's efficacy against specific bacteria in the target species and establishing appropriate withdrawal periods for food safety. Other research areas include target animal safety and the pharmacokinetics (absorption and metabolism) of the product.

Q: What is the half-life of Eficur in the body?

Pharmacokinetic data describes the time required for the drug concentration to decrease by half. The elimination half-life for the active metabolite, desfuroylceftiofur, is approximately 14.3 hours in swine and over 9 hours in cattle following intramuscular injection.

Q: Is it normal to feel a bit nauseous when first starting Eficur?

In the target animal species, official regulatory documents list Gastrointestinal Disorders, such as diarrhea or soft stool. Nausea itself is not specifically listed as a common or systemic side effect in the official regulatory documents for the target animals.

Q: What is the evidence regarding the long-term use of Eficur?

The officially approved treatment duration is short, typically limited to 3 to 5 consecutive days. Regulatory documents do not provide evidence for or recommend the use of the drug beyond this defined, short-term treatment course.

Q: Is there a maximum amount of time someone can safely take Eficur?

Official administration guidelines strictly limit the duration of use. The treatment course is defined as 3 consecutive days for swine and 3 to 5 consecutive days for cattle, depending on the condition being treated.

Q: What does official guidance say about using Eficur during breastfeeding?

The drug is officially approved for use in lactating dairy cattle. Its use is subject to the official milk withdrawal periods specified on the product label. These mandated periods are put in place by regulatory authorities to ensure food safety.

Q: Are there any documented cases of overdose with Eficur?

Target animal safety studies have investigated the effects of high doses. In pigs, the drug showed low toxicity at doses up to eight times the recommended amount. In cattle, no signs of systemic toxicity have been observed following substantial overdosages.

How should Eficur be stored and disposed of?

How to Store and Dispose of Eficur?

Official regulatory guidelines mandate specific conditions for storing and discarding the Eficur (Ceftiofur) suspension to maintain its stability.

Storage Requirements

Condition	Requirement
Temperature	Do not store above 25 C.
Prohibitions	Do not refrigerate or freeze the product.
Protection	Keep in the outer carton to protect from light.
Child Safety	Store out of the sight and reach of children.

Shelf-Life and Disposal

The medicine has an unopened shelf life of two years. Once the container is broached, the contents must be used within 28 days, after which any remaining product must be discarded. Disposal of unused Eficur or waste materials must be performed strictly in accordance with local requirements and should not be allowed to enter waterways.

Eficur